Sarepta Therapeutics, Inc.(SRPT)
Biotechnology
Rare Disease / Orphan Drug
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-03-13 | Mayo Stephen Director | Sale | -7,239 | -80.40%1,765 | $17.02 | $123,208 | View SEC filing | |
| 2025-12-18 | Estepan Ian Michael Chief Operating Officer | Sale | -13,187 | -6.39%193,300 | $22.31 | $294,202 | View SEC filing | |
| 2025-03-13 | Nicaise Claude Director | Sale | -2,491 | -8.22%27,812 | $99.64 | $248,203 | View SEC filing | |
| 2024-12-16 | Wigzell Hans Lennart Rudolf Director | Sale | -10,500 | -31.49%22,840 | $124.84 | $1,310,820 | View SEC filing | |
| 2024-12-06 | Boor Kathryn Jean Director | Sale | -1,636 | -21.77%5,880 | $125.55 | $205,400 | View SEC filing | |
| 2024-09-03 | Estepan Ian Michael Chief Financial Officer | Sale | -5,985 | -14.99%33,946 | $137.36 | $822,100 | View SEC filing | |
| 2024-08-20 | Chambers Michael Andrew Director | Purchase | +37,038 | +15.00%284,034 | $133.80 | $4,955,728 | View SEC filing | |
| 2024-06-25 | Brown Ryan Edward EVP, General Counsel | Sale | -38,957 | -69.46%17,129 | $161.61 | $6,296,029 | View SEC filing | |
| 2024-06-25 | Arif Bilal Chief Tech Ops Officer | Sale | -11,757 | -40.37%17,363 | $163.13 | $1,917,891 | View SEC filing | |
| 2024-05-06 | Murray Dallan Chief Customer Officer | Sale | -3,635 | -16.70%18,125 | $140.00 | $508,900 | View SEC filing | |
| 2024-03-11 | Wigzell Hans Lennart Rudolf Director | Sale | -15,000 | -39.64%22,840 | $123.25 | $1,848,795 | View SEC filing | |
| 2024-03-11 | Boor Kathryn Jean Director | Sale | -761 | -9.19%7,516 | $122.93 | $93,550 | View SEC filing | |
| 2024-03-06 | Mayo Stephen Director | Sale | -3,135 | -32.13%6,621 | $122.96 | $385,480 | View SEC filing | |
| 2024-03-05 | Brown Ryan Edward EVP, General Counsel | Sale | -2,000 | -5.91%31,827 | $125.34 | $250,680 | View SEC filing | |
| 2024-03-05 | Arif Bilal Chief Tech Ops Officer | Sale | -2,000 | -6.94%26,836 | $128.84 | $257,676 | View SEC filing | |
| 2024-03-05 | Estepan Ian Michael Chief Financial Officer | Sale | -1,200 | -2.98%39,114 | $128.30 | $153,960 | View SEC filing | |
| 2023-11-06 | Barry Richard Director | Purchase | +50,000 | +50.00%150,000 | $78.81 | $3,940,500 | View SEC filing | |
| 2023-11-06 | INGRAM DOUGLAS S President & CEO | Purchase | +25,225 | +6.91%390,307 | $79.36 | $2,001,800 | View SEC filing | |
| 2023-08-15 | Chambers Michael Andrew Director | Purchase | +9,979 | +4.21%246,996 | $109.47 | $1,092,429 | View SEC filing | |
| 2023-08-14 | Chambers Michael Andrew Director | Purchase | +23,686 | +11.10%237,017 | $108.05 | $2,559,272 | View SEC filing | |
| 2023-08-11 | Chambers Michael Andrew Director | Purchase | +34,867 | +19.54%213,331 | $106.15 | $3,701,067 | View SEC filing | |
| 2023-08-08 | Wigzell Hans Lennart Rudolf Director | Sale | -15,000 | -41.67%20,994 | $106.72 | $1,600,800 | View SEC filing | |
| 2022-11-21 | Mayo Stephen Director | Sale | -858 | -11.84%6,387 | $109.92 | $94,311 | View SEC filing | |
| 2022-09-15 | Chambers Michael Andrew Director | Purchase | +57,100 | +111.79%108,178 | $104.43 | $5,963,124 | View SEC filing | |
| 2022-08-22 | Chambers Michael Andrew Director | Purchase | +46,170 | +940.71%51,078 | $108.28 | $4,999,230 | View SEC filing |
1-25 of 148